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Abstract 
Mesenchymal progenitor cells (MPCs) represent an attractive cell population for bone tissue 
engineering. Their special immunological characteristics suggest that MPCs may be used in 
an allogenic application. The objective of this study was to compare the regenerative 
potential of autologous vs. allogenic MPCs in an ovine critical-sized segmental defect model. 
Ovine MPCs were isolated from bone marrow aspirates, expanded and cultured with 
osteogenic media for two weeks before implantation. Cells were seeded onto medical grade 
polycaprolactone-tricalcium phosphate scaffolds (mPCL-TCP) in combination with platelet 
rich plasma. Autologous and allogenic transplantation was performed by using the cell-
seeded scaffolds, unloaded scaffolds and the application of autologous bone grafts served 
as control groups (n=6). Bone healing was assessed twelve weeks after surgery by 
radiology, micro computed tomography, biomechanical testing and histology. No local or 
systemic rejection was observed after transplantation of allogenic cells. Radiology, 
biomechanical testing and histology revealed no significant difference in bone formation 
between the autologous and allogenic group. Both cell groups showed more bone formation 
than the scaffold alone, whereas the biomechanical data showed no significant differences 
between the cell-groups and the unloaded scaffolds. The results of the study suggest that 
scaffold based bone tissue engineering using allogenic cells offers the potential for an off the 
shelf product. , which would be desired from a health economic point of view, because such 
new tissue engineering concepts would drastically lower the therapeutical costs. Therefore, 
the results of this study serve as an important baseline for the translation of the assessed 
concepts into clinical application. 
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1.1. Introduction 
The most suitable cell source for scaffold-based bone engineering is still focus of much 
debate in the literature. There is no denying the potential of including a cell population within 
a tissue engineered construct (TEC) which is able to regenerate the host site; however, the 
best approach from a clinical point of view is yet to be determined. 
Several cell-based strategies aim to improve osteoinduction by the incorporation of cells with 
a high osteogenic differentiation potential such as bone marrow derived mesenchymal 
progenitor cells (MPCs). Gronthos et al. [1] have defined these cells as multipotent 
progenitor cells, which have the potential to differentiate into a variety of mesenchymal 
tissues such as bone, cartilage, tendon, ligaments, muscle, fat and dermis [2] [3, 4]; [5]. 
MPCs can be isolated from a variety of tissues [6-8] using different separation techniques 
and can be differentiated into the appropriate phenotype under defined culture conditions 
and the action of specific growth factors or cytokines [9]. These cells have shown their 
therapeutic potential in a number of in vivo studies for the regeneration of large bone defects 
and non-unions [10-14]. The supply of autologous MPCs is often limited and the pre-
operative preparations for effective isolation, expansion and differentiation is time consuming 
and labour intensive. For this reason, to acquire an adequate amount of cells for 
transplantation, the time period between cell isolation and cell transplantation is usually at 
least 4 – 6 weeks. Consequently, the major drawback of using an autologous cell source is 
two-pronged; limitations in cell numbers when utilising them immediately after extraction or 
the long time period and associated costs, which are necessary to expand the cells in vitro 
until a suitably number of cells is attained. However, the special immunological 
characteristics, which are evident with MPCs, suggest that MPCs could in fact be used 
successfully for non-autologous applications in bone tissue engineering [15, 16]. Allogenic 
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cell transplantation is a common therapeutical option and is in routine clinical use in the field 
of oncology [17, 18]. Translating the idea of allogenic cell-transplantation from oncology to 
orthopaedics could offer a new opportunity for the availability of MPCs for regenerative 
medicine as an “off the shelf product”. Before translating these new treatment concepts into 
a clinical application in orthopaedic and trauma surgery, rigorous evaluation of the respective 
cell populations in an adequate preclinical animal model are essential [19, 20]. 
Several animal models have been developed over the years to verify the practicality of 
different research bone regeneration concepts [21-23]. Among these, adult sheep offer the 
advantage of having a comparable body weight, a similar mineral composition of bone and 
similar metabolic and remodelling rates to humans and furthermore, long bone dimensions 
suitable for the use of human implants and prostheses, which is not possible in smaller 
species [24, 25]. Thus, our group has recently established a challenging ovine segmental 
bone defect model using 6 – 7 year old animals, which, at this age, display the secondary 
osteon remodelling which is characteristic of human bone. In our more clinically driven 
recent strategies we move towards defining an appropriate cell source for bone tissue 
engineering to circumvent the aforementioned disadvantages associated with autologous 
cell transplantation in favour of allogenic MPC sources [26].  
We hypothesize that allogenic MPCs do not show a clinically detectable immune response 
and have a similar osteogenic potential compared to autologous MPCs in a scaffold-cell 
based bone engineering concept. Therefore, the aim of the current study was to assess and 
compare the regenerative potential of autologous versus allogenic MPCs in combination with 
a mPCL-TCP scaffold in a critical sized segmental bone defect in sheep.  
 
2. Material and Methods  
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All reagents and consumables were purchased from Sigma-Aldrich unless stated otherwise. 
2.1. Scaffold fabrication and preparation  
Biodegradable scaffolds comprising medical grade poly-caprolactone (80 wt%) and β-
tricalcium phosphate (20wt%), (mPCL–TCP), (outer diameter: 20 mm, height: 30 mm, inner 
diameter: 8 mm) were produced by fused deposition modelling (FDM) (Osteopore 
International, Singapore). The dimensions of the scaffold were derived from radiographic 
analyses of the anatomical dimensions of 10 sheep tibiae. The structural parameters of the 
scaffolds were tailored by computer-aided design to result in a 70% porosity with 100% pore 
interconnectivity and a pore size of 350-500 μm. Filaments of 300 μm in diameter were 
deposited following a 0/90° pattern with a separation of 1200 μm (Fig. 1 F). The scaffolds 
had a compressive stiffness of 446.5 N/mm. This architectural layout is particularly suitable 
since the fully interconnected channel-like network supports not only the retention of the 
fibrin-network of the blood clot but can also withstand early physiological and mechanical 
stress in a manner similar to cancellous bone [27, 28]. Moreover, the architectural pattern 
allows retention of coagulating blood clots during the early phase of healing, and bone in-
growth combined with homogenously distributed vascularization at later stages. Prior to 
surgery, all scaffolds were surface treated for six hours with 1M sodium hydroxide (NaOH) 
and washed five times with phosphate-buffered saline (PBS) to render the scaffold surface 
more hydrophilic. Scaffold sterilization was achieved by incubation in 70% ethanol for 5 min 
followed by complete evaporation and subsequently UV irradiation for 30 min. 
2.2. Biomechanical testing of scaffold and internal fixation 
To investigate the mechanical behaviour of the implant-bone-scaffold construct, 
biomechanical testing was performed in vitro on six specimens. A fixation plate (10 hole 
Dynamic Compression Plate, Synthes, Switzerland) was affixed to a cylindrical bone 
analogue cut to a length of 240 mm (fibre-filled epoxy cylinder with a 20 mm outer diameter, 
3 mm wall thickness, Pacific Research Laboratories, Washington, USA). A 3 cm defect was 
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created in the bone analogue, afterwhich a mPCL-TCP scaffold was inserted into the defect. 
The ends of the construct were embedded in Paladur acrylic (Heraeus-Kulzer, Hanau, 
Germany) and the construct mounted in a biaxial materials testing machine (Instron 8874, 
MA, USA) using a custom-made jig [29]. The test area was enclosed and heated to 37 
degrees. The specimen was subjected to 5 cycles with the last cycle used for analysis. The 
custom-made jig was used to simulate three load cases; confined axial compression (500 
N), axial torsion (7 Nm) and medial-lateral bending (10 Nm). To determine the 
interfragmentary movements (IFMs) at the centre of the defect, optical marker rigid bodies 
(Orthopaedic Research Pins, Northen Digital Inc, Ontario, Canada) were affixed to the 
proximal and distal fragments of the bone-analogue. The displacements of the rigid bodies 
were captured via a motion capture system (Optotrak Certus, Northen Digital Inc, Ontario, 
Canada) and the IFMs calculated using matrix algebra. The test was then repeated with the 
scaffold removed from the construct. 
2.3. Cell harvesting  
All reagents were purchased from Sigma-Aldrich unless stated otherwise. Ovine 
mesenchymal progenitor cells (MPCs) were obtained from 6-7 years old Merino sheep 
undergoing experimental surgery. Bone marrow aspirates were obtained from the iliac crest 
under general anaesthesia (Fig. 1 A). Total bone marrow cells (5-15 x 106 cells/ml) were 
plated at a density of 10-20 x 106 cells/cm2 in complete medium consisting of low glucose 
DMEM supplemented with 10% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin. Cells 
were subsequently plated at a density of 103 cells/cm2 (Fig. 1 B). We have demonstrated 
previously that MPCs express the respective phenotypic profile typical for different 
mesenchymal cell populations and show a multilineage differentiation potential.[30] Two 
weeks before implantation, the medium was changed to an osteogenic media (DMEM, 10% 
FBS, 100 U/ml penicillin and 100 µg/ml streptomycin, 10 µl/ml ß-glycerophosphate, 1 µl/ml 
ascorbic acid and 1 µl/ml dexamethasone) to induce osteogenic differentiation (Fig. 1 C). For 
3D cultures, 35 x 106 ovine MPCs suspended in 500 µl of basal medium were mixed with 
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platelet rich plasma (PRP) (described in subsequent section) and then seeded onto each 
mPCL-TCP scaffold (Fig. 1 G). PRP was activated with thrombin (5 U/ml), and the scaffolds 
were incubated at 37°C for at least one hour before implantation into the defect. 
2.4. Cell labelling with Bromodeoxyuridine 
Cells from one animal per experimental group were labelled with Bromodeoxyuridine (5-
bromo-2-deoxyuridine, BrdU, Invitrogen, Australia). Cells for labelling were seeded at a 
density of 3000/cm2 in DMEM/10% FBS and allowed to attach overnight. The day after 
seeding, BrdU labelling was achieved by incubating ovine MPCs with the BrdU labelling 
reagent (Invitrogen) at a concentration of 1:100 in DMEM/10% FBS for 6 h. BrdU is a 
synthetic nucleoside that is an analogue of thymidine. It can be incorporated into newly 
synthesized DNA of replicating cells substituting for thymidine during DNA replication thus 
labelling the respective cells. Specific antibodies may then be used to visualize the 
incorporated chemical.  
2.5. Preparation of platelet rich plasma  
To produce autologous platelet rich plasma (PRP), 80ml of blood was collected from the 
jugular vein of each sheep and transferred into 3.5 ml monovettes supplemented with 
sodium citrate (3.8%) at a ratio of 9 volumes blood and 1 volume sodium citrate according to 
Anitua et al. [31]. The citrated blood was transferred to falcon tubes and centrifuged in a 
standard laboratory centrifuge for 20 min at 2,400 rpm (580 g) (Fig. 1 D/E). Subsequently, 
the yellow plasma layer from all tubes was transferred to a fresh falcon tube and the 
platelets were pelleted in a second centrifugation step for 10 min at 3,600 rpm (1300g) [32]. 
The pellet was resuspended in 1.2 ml of plasma and the platelets counted in a Neugebauer 
counting chamber. After preparation, the PRP and cell suspensions were loaded onto the 
sterilized scaffolds (Fig. 1 G).  
2.6. Experimental groups/Surgical procedure 
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Twenty-four merino sheep (weight 45±2 kg, aged 6-7 years) were operated upon as 
approved by the University Animal Ethics Committee of the Queensland University of 
Technology, Brisbane, Australia (Ethics No.: 0900000906). The four experimental groups 
comprised two cell groups (allogenic and autologous cells), a scaffold only and an 
autologous bone graft (ABG) group, which served as a positive control.  
The animals were intubated with a 9-10 mm silicon endotracheal tube and connected to an 
automatic respirator (Campbell anaesthetic ventilator) for assisted ventilation with 2l O2/min. 
The general anesthesia was maintained with propofol (2%) at a rate of 120-140 ml/min. For 
analgesia, Buprenorphine (0.1 mg per 10 kg body weight) was administered. For surgical 
procedures, all animals were placed in the right lateral position. The right tibia was exposed 
by a longitudinal incision of approximately 12 cm length on the medial aspect of the limb 
(Fig. 2 A). A broad dynamic compression plate (DCP, 4.5 mm, 10 holes, Synthes) was 
adjusted to the anatomy of the bone by bending (plate-bending press, Synthes) and applied 
to the medial tibia. The distal end of all plates were placed 2.5 cm proximal of the medial 
malleolus (Fig. 2 B). All proximal and distal screw holes were drilled and the plate was 
temporarily fixed with 2 screws on each site of the anticipated 3 cm defect (Fig. 2 C). The 
middle of the defect site was determined and marked with a raspatory. A distance of 1.5 cm 
each proximally and distally of the defect centre was measured and marked to define the 
osteotomy lines (Fig. 2 D), [33].  
Next, the soft tissue inserting to the bone in the designated defect area was detached to 
avoid damage to the proximate nerve and blood vessels during the osteotomy. Parallel 
osteotomies perpendicular to the bone’s longitudinal axis were performed with an oscillating 
saw (Stryker) under constant irrigation with saline solution to prevent heat-induced 
osteonecrosis whilst the bone segment of 3 cm length was excised (Fig. 2 E/G). Care was 
taken to completely remove the periosteum within the defect area and additionally 1 cm 
proximally and distally of the osteotomy lines (Fig. 2 F, arrow). The plate (DCP) was fixed on 
the proximal bone using 4 screws. Afterwards, the scaffold was gently placed into the defect 
and the distal part of the tibia was fixed to the plate using 3 screws (Fig. 2 H/I). One DCP 
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hole was used to fix the scaffold between the proximal and distal segments under little 
pressure. The wound was closed in two layers with a 2-0 Monocryl (Ethicon) and a 3-0 
Novafil (Syneture) suture for the skin. The closed wound was sprayed with Opsite (Smith 
and Nephew), covered with pads and bandaged (Vetrap, 3M). After recovery from 
anaesthesia, animals were allowed unrestricted weight bearing. After 12 weeks, the animals 
were euthanized by intravenous injection of 60 mg/kg pentobarbital sodium (Lethabarb, 
Virbac, Australia).  
2.7. Post-operative monitoring 
All animals of the experimental groups underwent for the first four weeks after the surgical 
procedure on a daily base a routine clinical investigation by a veterinary surgeon to assess 
any evidence of an immune reaction to the implantation of the cells. Blood samples were 
taken from all animals on day 1, 3, 7, 14 and 21 after the operation from the allogenic group 
and from the autologous group as a control for basic analysis of immune reaction (e.g. white 
blood cell count). At the same time the sheep were physically examined. A final physical 
examination was performed six weeks after surgery and animals were observed weekly for 
the remainder of the study.  
2.8. Radiographic analysis 
Immediately after surgery, after six and twelve weeks, conventional x-rays were taken to 
determine the time of bridging of the defect in the different experimental groups (Philips, 
Australia). Conventional x-ray analysis (3.2 mAs; 65kV) was performed in two standard 
planes (anterior-posterior and medial-lateral). The radiographic analyses after 3 month of an 
additional group, treated with mPCL-TCP scaffold and PRP were included in this study, to 
demonstrate the effect of PRP on bone regeneration.  
 
2.9. Computed tomography (CT) 
2.9.1. Clinical CT 
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A clinical CT scanner (Philips Brilliant CT 64 channels) was used to scan the experimental 
limbs. A dipotassium phosphate phantom was used to calibrate measurements of mineral 
density. 3D reconstructions from the CT data were generated with AMIRA® 5.2.2 (Visage 
Imaging GmbH, Berlin, Germany) (Visage Imaging) with a threshold of 300 and qualitative 
analysis was performed to assess mineralization within the defect and bridging. For 
quantitative analysis, the CT datasets of the operated tibia of each animal were edited by 
using the programs AMIRA® and Rapidform2006 (Inus Technology, Seoul, Korea). The 
amount of newly formed bone within the 3 cm defect area was calculated using an in-house 
MATLAB program (MATLAB 7.6.0, MathWorks, Inc., Natick, MA, USA).  
 
2.9.2. Microcomputed tomography (microCT)  
Samples were scanned (μCT 40, Scanco, Brüttisellen, Switzerland) with a voxel size of 36 
μm. The x-ray tube was operated at 55kV and 145 μA. Samples were evaluated at a 
threshold of 210, a filter width of 0.8 and filter support of 1.0 and analysed for bone volume 
and bone mineral density within the defect using the software supplied by the manufacturer. 
For the bone volume calculations, the regions of interest were determined as external callus 
formation (external), bone formation within the scaffold (scaffold) and bone formation in the 
inner part of the scaffold (endosteal).  
 
2.10. Biomechanical testing 
For biomechanical testing both tibiae of each sheep were explanted and the fixation plate of 
the experimental leg was carefully removed. Both ends of the tibiae were embedded in 80 ml 
of Polymethylmethacrylate (PMMA) (Paladur, Heraeus Kulzer, Germany) and each bone 
was then mounted in an Instron 8874 biaxial testing machine. By leaving as much soft tissue 
as possible attached in the region of the defect site, bone samples were prevented from 
drying out. Next, for the experimental and the intact tibia (control) a torsional test until failure 
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was performed in a biaxial universal testing machine (Instron 8874, Instron, Norwood, USA). 
The torsion test was conducted with a compressive load of 0.05kN and at an angular velocity 
of 0.5 deg/s until the fracture point was reached (right tibiae counter clockwise, left tibiae 
clockwise). In order to avoid the possibility of damage to the specimens in the early stages of 
bone healing, no preconditioning of the samples was performed. The torsional moment (TM) 
and torsional stiffness (TS) values were calculated from the slope of the torque-angular 
displacement curves and normalized against the values of the intact contralateral tibiae. 
 
2.11. Histology/Immunohistochemistry 
After biomechanical testing and microCT analyses, tibial bone specimens were trimmed to 6 
cm length and fixed in 10% neutral buffered formalin for 1 week. For histological analysis, 
the mid-defect regions were sectioned in the transverse and sagittal plane. The sagittal 
sectioned samples were used for paraffin embedding. To process the samples for paraffin 
embedding, bone samples were decalcified in 15% EDTA for 6-8 weeks at 4 °C. The 
samples were then serially dehydrated in ethanol in a tissue processor (Excelsior ES, 
Thermo Scientific, Franklin, MA, USA), and embedded in paraffin. Samples (5 µm) were 
sectioned using a microtome (Leica RM 2265). The slides were then deparaffinised with 
xylene and rehydrated before staining with haematoxylin and eosin (Sigma Aldrich) and 
mounting with Eukitt mountant (Fluka Biochemica, Milwaukee, WI, USA). The remaining 
samples were used for undecalcified embedding in methylmethacrylate resin (Technovit 
9100 NEU, Heraeus Kulzer, Wehrheim, Germany). Longitudinal sections were performed 
with a thickness of 6 µm and stained with von Kossa/McNeal’s Tetrachrome to identify new 
bone formation and Goldner’s Trichrome to identify cellular details. For 
immunohistochemistry, paraffin sections were deparaffinised with xylene and rehydrated 
with serial concentrations of ethanol. Subsequently, sections were rinsed in distilled water 
and placed in 0.2 M Tris-HCl buffer (pH 7.4). Endogenous peroxidase activity was blocked 
by incubating the sections in 3% H2O2 in Tris-HCl for 20 min. This was followed by three 
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washes with Tris buffer (pH 7.4) for 2 min each. Sections were incubated with Proteinase K 
(DAKO, Botany, Australia) for 20 min and subsequently incubated with 2% bovine serum 
albumin (BSA) (Sigma, Sydney, Australia) in DAKO antibody diluent (DAKO) in a humidified 
chamber at room temperature for 60 min to block non-specific binding sites. Afterwards, 
immunohistochemical staining was performed using primary antibodies specific to the 
osteogenic markers: type I collagen (Abcam, Cambridge, UK) and osteocalcin (Abcam, 
Cambridge, UK). The sections were incubated with the specific antibody in humidified 
chambers at 4°C over night. Sections were then washed three times for 2 min with Tris 
buffer (pH 7.4) and incubated with peroxidase labelled dextran polymer conjugated to goat 
anti-mouse and anti-rabbit immunoglobulins (DAKO EnVision+ Dual Link System 
Peroxidase, DAKO) at room temperature in humidified chambers for 60 min. Colour was 
developed using a liquid 3,3-diaminobenzidine (DAB) based system (DAKO). Kaiser’s 
glycerol gelatin (DAKO) was used for coverslip mounting.  
For detection of BrdU labelled cells, a Zymed® streptavidin-biotin based system for BrdU 
staining (Invitrogen) was used on paraffin sections according to the manufacturer’s protocol.  
 
2.12. Statistical analysis 
Statistical analyses for the biomechanical results, the blood samples and for the computed 
tomography scans (clinicalCT and microCT) were carried out using a two-tailed Mann-
Whitney-U-test (SPSS 17.0, SPSS Inc.) and p-values are adjusted according to Bonferroni-
Holm. Results were considered significant for p<0.0085.  
3. Results 
No postoperative infections or other complications were observed in any of the animals. All 
animals were in good health and survived the experimental period gaining weight in the 
months following surgery. Notably, the animals of the allogenic group showed no clinical 
signs of immune response.  
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3.1. Biomechanical testing of scaffold construct (prior to implantation) 
Under an axial compression load of 500 N the interfragmentary movement in the defect was 
0.27 mm giving an interfragmentary strain (IFS = IFM/gap-size) of less than 1%. There was 
minimal difference in the IFM (0.21 mm) under compression with the scaffold removed. 
Subjected to torsion (7 Nm) the construct underwent a relative rotation of the bone 
fragments of 7.4 deg. Medial-lateral bending induced by an axial load of 100 N at an offset of 
10 cm resulted in a shortening of the defect axially by 4.0 mm (IFS 13%) with a bending 
angle of 1.9 deg. 
3.2. Monitoring of immune response 
Venous blood samples were taken preoperatively and on day 1, 3, 7, 14 and 21 after the 
operation from all the animals of the allogenic group and selected animals of the autologous 
group (control). The blood tests showed no signs of graft rejection. Preoperatively, the 
results of the white cell count (WCC) in the allogenic group were slightly higher compared to 
the autologous group (p=0.11), and did not increase more than in the autologous group after 
surgery (p=0.41) (Fig. 3). 
3.3. Radiographic analysis 
Conventional x-ray analyses in two standard planes (anterior-posterior and medial-lateral) 
were performed to assess bone formation. After surgery, the correct position of the scaffold, 
the plate and the screws were confirmed. The x-ray analysis after 3 month showed no 
loosening of the plate & screws or movement of the scaffolds in all experimental groups. 
External callus and bone formation within the defect was observed in all animals of the 
autologous and the allogenic cell group (Fig. 4 B/C). A complete bridging of the defect was 
only observed in one animal of the allogenic group and two animals of the autologous group. 
The groups treated with mPCL-TCP scaffold (A) showed no radiographic signs of bone 
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formation within the defect. The defect treated with autologous bone graft (ABG) (D) showed 
clear radiographic signs of bone formation with defect bridging in the x-rays.  
3.4. Computed tomography (CT) 
3.4.1. ClinicalCT 
Qualitative CT analysis after 12 weeks showed bone formation within the defect in both 
experimental cell groups (Fig. 5 A, B). Minor bone formation was seen in the mPCL-TPC 
scaffold group, whereas a full defect bridging had occurred in all defects reconstructed with 
ABG (p=0.093) (positive control group). No radiographic signs of inflammation (e.g. diffusely 
delimited soft tissue infiltrations, osteolysis, osteomyelitis, abscesses) were found. Scaffolds 
showed good osseointegration without any signs of resorption. Median values of total bone 
volume (BV) in the defect were higher in the allogenic cell group compared to the autologous 
cell group (p=0.307). Furthermore, both cell groups showed a higher total bone volume 
compared to the scaffold only group (Fig. 5 G). However, the differences were not 
statistically significant (p=0.208; p=0.153).  
3.4.2. MicroCT 
MicroCT analysis confirmed the trends observed with the clinical CT scans regarding union 
rates and the amount of new bone formation (Fig. 5 C, D). In both cell groups, the mean 
values of newly formed bone were higher compared to the scaffold only group (p=0.027; 
p=0.062) (Fig. 5 E). Highest median values of newly formed bone were found for the ABG 
group, which were significantly higher compared to the scaffold only group (p=0.002), but 
were not significantly different to both cell groups (p=0.208; p=0.308) (Fig. 5 E). However, 
even in the ABG group, newly formed bone still only reached levels equating to 50% of that 
determined for the same anatomic level of the contralateral hind limbs (control) (Fig. 5 E). 
The amount of new bone was distributed equally throughout the external, scaffold and 
endosteal area of the defect (Fig. 5 F). A tendency towards a higher volume of bone 
formation in the allogenic cell group compared to the autologous cell group and the scaffold 
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only group was observed (p=0.734) (Fig. 5 F). The tissue mineral density of the regenerated 
bone showed similar results in all experimental groups of approximately 60 – 80% of the 
contralateral tibia (Fig. 5 H). 
3.5. Biomechanical testing 
Biomechanical testing was performed on all operated groups (right tibiae) as well as the non-
operated left tibiae, which served as a control (Fig. 6 A). Biomechanical testing revealed an 
equal torsional stiffness (TS) for the autologous and the allogenic cell groups (p=0.73) (Fig. 
6 B) and slightly higher values for the torsional moment (TM) for the autologous group 
(p=0.61) (Fig. 6 C). Both cell groups showed a higher torsional moment (p=0.093; p=0.174), 
but a comparable torsional stiffness compared with the scaffold only group (p=0.012; 
p=0.062). The samples of the ABG group showed the highest values for torsional moment 
and torsional stiffness, however they only reached approximately 15 to 20% of that obtained 
from the contralateral non-operated side (control). No significant differences were found 
between all the groups by biomechanical testing (p=0.021). 
3.6. Histology/Immunohistochemistry 
The macroscopic overview of the implanted scaffolds before processing for histology 
showed a good integration of the scaffold to the host bone in all animals (Fig. 7 A). The 
mPCL-TCP scaffold was still in place and had not resorbed. Histological examinations of 
decalcified samples were performed after 12 weeks. Representative H&E staining of both 
cell groups demonstrated a good integration of the scaffold to the host bone on the proximal 
as well as the distal side (Fig. 7 B, C, F, G). Notably, new bone formation was seen in many 
pores within the mPCL-TCP scaffolds in both cell groups (the scaffold itself is revealed in the 
histology slices as empty circular “holes”  and “bars” where the scaffold struts used to reside, 
due to the dissolution of the PCL implant by xylene during processing) (Fig. 7 B-G).   
Undecalcified sections (MMA resin-embedded) were stained with von Kossa/McNeal’s to 
identify new mineral deposition. Both cell groups showed mineral deposition (black stain) 
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within the defect (Fig. 8 B, G). These results confirm our microCT and clinicalCT evaluation 
and demonstrate a limited amount of bone tissue growing into the whole scaffold area. 
Furthermore, the large overview pictures of the Goldner’s Trichrome staining demonstrate 
the presence of collagen fibres in the scaffold and surroundings (Fig. 8 A, F). New bone 
formation is traditionally accompanied by the expression of bone specific proteins within the 
extracellular matrix surrounding the osteoblasts, this may be detected using 
immunohistochemistry. As an early non-specific marker of osteoblastic differentiation during 
mineralisation, type I collagen showed a similar intensity in both cell groups (Fig. 8 D, I). 
Immunohistochemical staining for osteocalcin also demonstrated similar expression levels 
with a high expression of this late osteogenic marker localised around the scaffolds struts 
(labelled “s”) (Fig. 8 E, K). The staining to detect the BrdU labelled cells did not reveal any 
evidence of survival of the donor cells (data not shown). 
4. Discussion 
The use of allogenic cells for clinical therapy is already established and in routine use in 
areas of medicine such as oncology and a large number of clinical trials are currently 
performed in cardiology [34, 35]. Our results demonstrated that allogenic bone marrow-
derived mesenchymal progenitor cells (MPC’s) can be safely delivered in an in scaffold-
based bone regeneration in a large segmental defect model in sheep. In addition to their 
osteogenic potential, it has been shown that MPCs are immunologically privileged making 
them highly appropriate for the use in allogenic cell transplantation concepts [36] and indeed 
we observed no immune response in a preclinical animal model. Furthermore, Niemeyer et 
al. (2007) demonstrated that MPC’s retain their immunological properties after osteogenic 
induction in vitro.  The allogenic application of MPCs showed similar results for bone 
regeneration compared to the autologous cell group, with associated advantages of an 
allogenic cell source (easy to access and high abundance compared to autologous cells). 
After the transplantation, the sheep were monitored by clinical examination and by taking 
blood samples. Our results are in line with observations from Guo et al. who described that 
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allogenic mesenchymal progenitor cells raised a minimal immunological reaction only in the 
early stages after implantation in a study in mini-pigs [37].  
Moreover, next to that we did not observe any clinically detectable foreign body reaction or 
cell rejection we did not detect anyand no different cellular reactions in the histological 
assessment compared to the autologousin both cell groups in the histological assessment 
throughout the defect which demonstrated, once more, the low immunological activity of 
allogenic BMPC’s. While the limited availability and the donor site morbidity of autologous 
bone grafts is often discussed and stated as a major disadvantage of this technique, the use 
of an allogenic cell source with comparable regeneration potential as a potential off-the-
shelf-product would open new routine therapeutic potentials for the regeneration of large 
bone defects [38, 39].  
In a more recent study, human BMPCs in combination with a collagen type I scaffold were 
implanted into a critical sized defect of the sheep tibia and compared with autologous ovine 
BMPCs [40]. The autologous BMPCs demonstrated better bone formation compared to the 
human MPCs and cell-free scaffolds in the histological and radiological evaluation. However, 
the bone regeneration was evaluated based on two dimensional imaging procedures and the 
study lacked microCT analyses and biomechanical testing, which would provide a greater 
depth of understanding of the structural and morphological characteristics and more 
importantly the functionality of the regenerated bone. Field et al. (2011) evaluated the 
efficacy of allogenic mesenchymal progenitor cells seeded on HA-microparticles for the 
repair of an ovine tibial segmental and reported a higher osteogenic regeneration potential of 
the allogenic group compared to the scaffold only group combined with better biomechanical 
properties and more bone formation.  
Yet, studies by Field et al. and Niemeyer et al. used different fixation methods (double plate 
fixation vs. intramedullary nail) and different experimental protocols, which render a one to 
one comparison of these findings difficult. For example, fixation with a medullary nail will 
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result in blocking the medullary cavity of the tibia, which might reduce the regeneration 
potential in this endosteal area. Furthermore, different fixation methods result in different 
biomechanical environments, such as more flexibility and a central mechanical loading (nail) 
compared to a much stiffer fixation by using a double plate fixation. Our biomechanical 
analysis of the DCP-plate fixation showed, under static loading conditions of up to 500 N, a 
minimal displacement of the scaffold of less than 1 %. Conclusively, the DCP fixation results 
in a stable fixation.  
As bone tissue engineering has become ever more prevalent over recent years, evaluating 
the different strategies with respect to potential clinical application in humans requires in vitro 
testing and small animal models and importantly, in the final stages, the use of standardised 
large animal models which are imperative for rigorous preclinical evaluation [41]. Thus, large 
preclinical animal models which use animals with comparable body weight, long bone 
dimensions, similar mineral composition, equivalent remodelling rates as well as established 
and standardised evaluation processes are essential to make sufficient predictions about the 
potential clinical success or failure of new bone tissue engineering strategies [19, 20]. Over 
the last decade, the sheep has become a very important and useful model to address 
research problems and holds specific advantages compared to other large animal models 
(e.g. pig, dog) such as long bone dimensions, ease of handling, calm nature, and the ability 
to keep them in large numbers at relatively low costs. However, it is important to note that 
secondary bone remodelling is only seen in older sheep making them comparable to human 
bones [42].  
Our group has established a critical-sized segmental tibial defect model in geriatric  sheep 
(7-8 years old) to address different bone tissue engineering approaches by testing 
combinations of growth factors, scaffolds and different cell types [20, 26, 43]. Compared to 
studies by other groups, this current model is a particularly challenging model using older 
sheep which are on the one hand more relevant to human bone but on the other hand have 
a lower general health status compared to younger animals. Some other groups only resect 
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the periosteum on the proximal and the distal bone, however, we have shown in a 
preliminary study, that the periosteum on the dorsal side between the tibia and the muscles 
which is closed to the vascular bundle (see back arrow Fig. 2F) contains a significant 
regeneration potential based on the MPCs from the cambium layer [26]. To our knowledge, 
we are the first group who developed a large segmental tibial defect model, which also 
includes the removal of this part of the periosteum, which represents 30-40% of the whole 
volume of the periosteum within the defect. As a result of the complete removal of the 
periosteum and the age-related compromised regenerative capacity, it is not surprising that 
we revealed lower biomechanical stability (TM 10-15% and TS 20-25% of contralateral tibia) 
after three month even in the ABG group compared to other research groups who even 
present significantly higher results in their control groups [44, 45]. This demonstrates, once 
again, the importance of standardised large animal models with validated experimental 
protocols to compare outcomes of each different bone engineering approach. This is a 
condition sine qua non to move concepts from bench to bedside. 
The present study showed effectively that allogenic MPCs can be safely used in combination 
with a mPCL-TCP scaffold for bone regeneration in a critical sized bone defect in a 
preclinical animal model. None of the animals of the study showed a rejection of the TECs or 
a foreign body reaction in form of a fibrous tissue encapsulation. The allogenic and the 
autologous cell groups showed comparable results with respect to biomechanical properties 
and new bone formation. The biomechanical evaluation showed a small difference between 
the cell groups and the scaffold-only group, whereas the bone volume analysis using 
clinicalCT and microCT showed larger differences between these groups. We detected more 
bone volume in both cell groups compared to the empty scaffold groups, which 
demonstrated that autologous as well as allogenic cell transplantation leads to enhanced 
bone formation in a critical sized segmental defect model. Our recently published results 
demonstrate that we have developed and validated the most challenging preclinical animal 
model for large segmental defects, and hence within the three month time period of this 
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study, the bone regeneration was still in its early progress phase and most of the defects 
were not completely bridged which resulted in low biomechanical test results [43]. Other 
studies using a less challenging (2- year old sheep, no removal of periosteum) critical sized 
segmental tibial defect in a large animal had longer time frames for their experiments, which 
logically resulted in more bone formation and higher biomechanical stability [14]. As we were 
specifically interested in considering the immune response and the safety of delivering 
allogenic MPCs at this stage of our research we intentionally chose an early time point. A 
common practice to improve the biological competence of osteoconductive scaffolds is via 
incorporation of osteogenic induction stimuli such as bone morphogenetic proteins (BMP), 
vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF). 
Platelet rich plasma (PRP) contains several growth factors including significant amounts of 
VEGF and PDGF and has been in clinical use for many years especially in the dental 
surgery field. However the benefits of PRP are still ambiguous regarding large bone defect 
regeneration in the orthopaedic arena, whereas the positive effect of BMPs for bone 
regeneration has been shown extensively in several small and large animal models as well 
as in the clinic [46-50].  
Because of the similarity to clinically approved and routinely used fibrin glue, PRP converts 
from a liquid state into a fibrin hydrogel in the solid state after being activated by thrombin 
and therefore it is used in several studies as a highly biocompatible cell-loading vehicle [51]. 
We could demonstrate in previous experiments that the scaffold-PRP construct used for 
large bone defects didn’t have significant effects regarding bone regeneration when 
compared to the scaffold only group after 3 month (unpublished data). Therefore, the 
analyses of this study focussed on the two cell groups. However, PRP can be used as a very 
effective cell delivery vehicle in a scaffold design with a channel-like architecture with large 
pores and large pore interconnections which allow full vascularization in a 3 cm segmental 
bone defect. The evaluation of the bone volume using both clinical- and micro-CT scanning 
showed slight differences in the raw data (absolute values) due to the different resolutions as 
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well as the different phantoms used for calibration; however the trend was the same. The 
experimental groups all showed a comparable tendency with respect to the contralateral tibia 
of the animals (Fig. 5 F). Keeping in mind the concept of translational research which might 
result in a later clinical application, the assessment of the correlation between clinicalCT 
scanning and microCT scanning becomes important, especially for future interpretation of 
clinicalCT scanning results from large bone defects in humans, as these may be directly 
related to the CT-results of the large animal studies. Beside the CT-scanning, which is 
essential for the 3D-reconstruction overview and analysis of the bone volumes, the 
histological evaluation plays an important role for a detailed evaluation not only of the 
regenerated bone but also the host tissue on a cell-based level. Therefore, in our opinion, 
next to biomechanical testing both evaluation methods (CT-scanning and histology) are 
required to perform a reliable study to analyse different tissue engineering approaches for 
bone regeneration. The use of cell-based tissue engineering strategies is often compromised 
due to a low survival rate off the implanted cells. To prove the effect of the transplanted cells, 
different labelling methods are available to demonstrate the survival of the transplanted cells 
at the end of the experiment [52]. Among these, BrdU-labelling is a straightforward method 
of cell labelling showing good results in small animal models. However, despite the potential 
shown using small animal models, we were not able to detect any BrdU-labelled cells in the 
large bone defect model [30]. This may be due to labelling the cells in passage 1 but then 
expanding the labelled cells extensively. We used cells of passage 3-4 for the in vivo 
experiments due to the need for high amounts of cells required for the experiment; hence the 
proliferation of the cells may have led to a loss of signal. Li et al. reported a decreasing of 
the labelling signal of BrdU over time, describing that the percentage of BrdU-positive cells 
decreased from 94% in passage 0 down to 18% in passage 2 [52]. Therefore, for the use in 
large segmental bone defects such as our sheep model, another labelling method would be 
more appropriate [53, 54] and several stable transfection techniques are currently 
investigated in our laboratory. 
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In conclusion, from an ethical as well as an economical point of view, it would be desirable to 
be able to directly compare the potential of different bone tissue engineering strategies in 
preclinical animal models to lower the costs and the number of animals and to realise the 
translation of novel concepts from research to clinical practice. Therefore, the bone tissue 
engineering community should advocate the combination of radiological, biomechanical, 
histological and immunhistochemical evaluations as necessary methodologies for an 
efficient and robust analysis of bone engineering strategies [55].   
The present study showed promising data using an allogenic compared to autologous cell 
source for regeneration of critical sized segmental bone defects in a large preclinical animal 
model. The use of allogenic or autologous cells combined with a mPCL-TCP scaffold 
showed no statistical differences in their bone regeneration potential as demonstrated by 
radiological, immunohistochemical, histological and biomechanical results. We furthermore 
detected no clinical signs of a immunological reaction. In the future, the successful 
translation from bench to bedside of allogenic cell transplantation into clinical practice could 
provide beneficial treatment alternatives for challenging bone defects.  
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Figure Legends 
 
 Fig. 1: Bone marrow aspirations (10 ml) from the iliac crest were performed under general 
anaesthesia (A). MPCs were typically elongated in shape after a culturing period of 10-14 days in 
expansion media (B) (scale bar=100µm). Cell shape changed to a more compact cobblestone-like 
appearance within days after being exposed to osteogenic media (C) (scale bar=100µm). The insert 
in (C) shows alizarin red staining of MPC cultures after 14 days on 6-well plates. Under osteogenic 
conditions MPCs secreted a mineralized matrix, whereas the control cultures didn’t reveal any 
staining. To prepare PRP, blood was collected from the jugular vein of the sheep, mixed, and 
transferred into falcon tubes (D). After centrifugation at 2,400 rpm for 20 min, the plasma was 
removed and centrifuged a second time (E). The resulting pellet was resuspended in 1.2 ml of 
plasma, and the cells in combination with PRP were seeded onto the scaffolds (G). A microCT image 
of the cylindrical mPCL-TCP scaffold produced via fused deposition modelling for segmental bone 
defect repair is depicted in (F) (scale bar=5mm).  
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Fig. 2: To create a 3 cm segmental defect, a skin incision was made over the medial part of the tibia 
(A), the plate was placed 2.5 cm proximal of the medial malleolus (B) and temporarily fixed with two 
screws (C). The screw holes were drilled and the defect middle and osteotomy lines were marked 
(black arrow, D). The bone segment was removed after creating a 3cm defect with an oscillating saw 
(black arrow, E; G). Care was taken to completely remove the periosteum (black arrow, F), which was 
closely located to to the vessels and the nerve in the dorsal part. After implanting the scaffold (*) (H), 
the proximal and distal bone of the tibia were realigned and fixed with a DCP plate and screws (I). 
Fig. 3: White cell count (WCC) of venous blood samples of all animals 
from the autologous allogenic (blue column) and allogenic autologous 
(red column) experimental groups (n=12) was performed to study the 
immunological response of the cells. No significant differences were 
found between the groups (p<0.0085).  
 
Fig. 4: Representative x-ray images of the experimental groups after 3 month. The groups treated 
with the scaffold only (A) showed no bone formation within the defect after 3 month. The defects 
reconstructed with mPCL-TCP scaffolds seeded with autologous MPC’s (B) and with allogenic MPC’s 
(C) show clear radiographic signs of a beginning defect bridging in both cell groups (white arrow) on 
the site of the neurovascular bundle (see arrow figure). The defect treated with autologous bone graft 
(ABG) showed the highest amount of bone formation in the defect with clear radiographic signs of 
defect bridging (D).  
 
Fig. 5: Representative 3D clinicalCT data reconstructions (AMIRA 5.2.2) after 3 month of critical 
segmental bone defects showed a similar bone formation within the defect in the autologous cell 
group (A) and the allogenic cell group (B). The 3D reconstructions of the clinicalCT scans were 
performed with a threshold of 300 and combined with a 2D reconstruction using a lower threshold to 
show the soft tissue and the scaffold. Box plots demonstrating the median ± 1st and 3rd quartile. Error 
bars represent minimum and maximum values. MicroCT 3D reconstructions showed just a small 
amount of bone formation within the defect in the autologous cell group (C) (bar=5mm) as well as the 
allogenic cell group (D) (bar=5mm). The drill holes in the host bone, through which the screws 
inserted to attach the DCP plate may be observed in (C) and (D),(white asterisk). The microCT results 
depict the median amounts of newly formed bone within the 3 cm defects as a percentage of the 
contralateral control side (E). The amount of bone volume was distributed into external part (1), 
scaffold area (2) and the endosteal area (3). Both cell groups showed a slightly higher amount of 
bone formation within the scaffold area compared to the scaffold only group (F). The total bone 
volume (BV) after 12 weeks, as measured by clinicalCT and microCT, showed slight differences in the 
absolute values due to the different resolution of both scanning methods (G). The tissue mineral 
density of the regenerated bone in all experimental groups was approximately 60 – 80% of the 
contralateral tibia (H). Results were considered significant for p<0.0085.  
 
Fig. 6: For biomechanical testing, both ends of the tibia were embedded after 3 month in 
Polymethylmethacrylate with the tibial axis vertically aligned (A). Box plots demonstrating median 
values ± 1st and 3rd quartile of torsional stiffness (B) and torsional moment (C) in relation to the 
contralateral tibia. Error bars represent maximum and minimum values. Both cell groups showed a 
higher torsional moment, but a comparable torsional stiffness compared with the scaffold only group. 
The samples of the ABG group showed the highest values for torsional moment and torsional 
stiffness. Results were considered significant for p<0.0085.  
 
Fig. 7: Macroscopical overview of the scaffold/cell constructs within the defect after explantation after 
3 month (A). Representative H&E staining of both cell groups of the proximal (B, C) (longitudinal 
sections), middle (D, E) (transverse sections) and distal (F, G) (longitudinal sections) parts of the 
defect showed a good integration of the scaffold (S) as well as a good bonding of the regenerated 
bone to the host bone (HB), (B-G; bar=0.5cm). The solvents used during the preparation of the 
histological sections resulted in the mPCL–TCP scaffold material being dissolved during embedding. 
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Hence mPCL–TCP struts (S) are represented in histological sections as empty “holes” of similar 
geometry. 
 
Fig. 8: Overview pictures of the undecalcified resin-embedded samples after 3 month, sectioned and 
stained with von Kossa/McNeal’s (B, G; bar=0,5cm) and Goldner’s Trichrome (A, F) demonstrated the 
mineralized tissue within collagen fibres (black arrows). Decalcified samples were stained with H&E 
(C, H), collagen type I antibody (D, I) and osteocalcin antibody (E, K); (bar in C-E, H-K=100µm). 
Representative stainings of both cell groups showed a good integration of the scaffold (scaffold strut 
labelled s) as well as a good bonding of the regenerated bone (NB) to the host bone (HB)(black 
arrows in E, H, I and K). The solvents used during the preparation of the histological sections resulted 
in the mPCL–TCP scaffold material being dissolved during embedding. Hence mPCL–TCP struts (S) 
are represented in histological sections as voids of similar geometry. 
 
